Recombinant interferon‐α2a hastens the rate of HBeAg clearance in children with chronic hepatitis B
Cristiana Barbera, Flavia Bortolotti, Carlo Crivellaro, Alessandra Coscia, Lucia Zancan, Paolo Cadrobbi, Gabriella Nebbia, Maria Nazarena Pillan, Loredana Lepore, Teresa Parrella, Giuseppe Dastoli, Maurizia R. Brunetto, Ferruccio Bonino – 1 August 1994 – We conducted a prospective controlled study of the efficacy of recombinant interferon‐α2a in 77 children (44 boys, 33 girls, mean age 8 yr) with chronic hepatitis B. All patients had seropositive results for HBeAg and hepatitis B virus DNA; 52 had chronic persistent or nonspecific reactive hepatitis, and 25 had mild active hepatitis.